Trials / Completed
CompletedNCT01968720
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Catabasis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of multiple doses of CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total triglycerides and chylomicron triglyceride levels in patients with severe hypertriglyceridemia. This is a single-blind study. All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAT-2003 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2013-10-24
- Last updated
- 2015-08-14
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01968720. Inclusion in this directory is not an endorsement.